29 junio 2007
Spisulosine , Poster en el Congreso celebrado en Berlin del 26 al 29 Junio 2007 .
Enantioselective intramolecular aziridination starting from sulfamates : application to the synthesis of Spisulosine .
Audrey Estéoule*1, Loïc Leman1, Fernando Duran2, Philippe Dauban1, Robert H. Dodd1; 1ICSN, France, 2Universidad de Buenos Aires, Argentina
Audrey Estéoule*1, Loïc Leman1, Fernando Duran2, Philippe Dauban1, Robert H. Dodd1; 1ICSN, France, 2Universidad de Buenos Aires, Argentina
Pharma Mar Nueva Patente : TRATAMIENTO DE LAS ENFERMEDADES DEL CÁNCER POR APLIDIN .
BEHANDLUNG VON KREBSERKRANKUNGEN DURCH APLIDIN .
Publication number: AT363910T
Publication date: 2007-06-15
Inventor: FAIRCLOTH GLYNN THOMAS (US); TWELVES CHRIS (GB); PAZ-ARES LUIS (ES)
Applicant: PHARMA MAR SA (ES)
Classification: - international: A61K9/08; A61K35/56; A61K31/136; A61K31/205; A61K31/4015; A61K38/00; A61K38/15; A61K38/17; A61K45/00; A61P35/00; A61K9/08; A61K35/56; A61K31/136; A61K31/185; A61K31/4015; A61K38/00; A61K38/15; A61K38/17; A61K45/00; A61P35/00; - European: A61K31/205; A61K38/15 Application number: AT20000976137T 20001115 Priority number(s): GB19990027006 19991115; GB20000005701 20000309; GB20000007639 20000329; GB20000015496 20000623; GB20000025209 20001013 .
Abstract not available for AT363910T
Publication number: AT363910T
Publication date: 2007-06-15
Inventor: FAIRCLOTH GLYNN THOMAS (US); TWELVES CHRIS (GB); PAZ-ARES LUIS (ES)
Applicant: PHARMA MAR SA (ES)
Classification: - international: A61K9/08; A61K35/56; A61K31/136; A61K31/205; A61K31/4015; A61K38/00; A61K38/15; A61K38/17; A61K45/00; A61P35/00; A61K9/08; A61K35/56; A61K31/136; A61K31/185; A61K31/4015; A61K38/00; A61K38/15; A61K38/17; A61K45/00; A61P35/00; - European: A61K31/205; A61K38/15 Application number: AT20000976137T 20001115 Priority number(s): GB19990027006 19991115; GB20000005701 20000309; GB20000007639 20000329; GB20000015496 20000623; GB20000025209 20001013 .
Abstract not available for AT363910T
28 junio 2007
27 junio 2007
26 junio 2007
Pharma Mar consigue la Patente de una Nueva Familia de AntiCancerigenos derivados de la Esponga Theonella Swinhoei .
ANTITUMOUR COMPOUNDS .
Publication number: WO2007068776
Publication date: 2007-06-21
Inventor: MARTIN LOPEZ MA JESUS (ES); REYES BENITEZ JOSE FERNANDO (ES); FERNANDEZ RODRIGUEZ ROGELIO (ES); FRANCESCH SOLLOSO ANDRES (ES); CUEVAS MARCHANTE MARIA DEL CAR (ES); COELLO MOLINERO LAURA (ES)
Applicant: PHARMA MAR SA (ES); MARTIN LOPEZ MA JESUS (ES); REYES BENITEZ JOSE FERNANDO (ES); FERNANDEZ RODRIGUEZ ROGELIO (ES); FRANCESCH SOLLOSO ANDRES (ES); CUEVAS MARCHANTE MARIA DEL CAR (ES); COELLO MOLINERO LAURA
(ES) Classification: - international: C07D493/18; A61K31/357; A61P35/00; C07D311/00; C07D323/00; C07D493/22; C07D493/00; A61K31/357; A61P35/00; C07D311/00; C07D323/00; - European: Application number: WO2006ES00687 20061214 Priority number(s): ES20050003092 20051215
Abstract of WO2007068776 The invention relates to novel antitumour compounds having general formula (I) and to the corresponding pharmaceutically-acceptable salts, derivatives, pro-drugs and stereoisomers thereof. The inventive compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. Said compounds have a cytotoxic activity and can be used for the treatment of cancer.
Abstract of WO2007068776 The invention relates to novel antitumour compounds having general formula (I) and to the corresponding pharmaceutically-acceptable salts, derivatives, pro-drugs and stereoisomers thereof. The inventive compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. Said compounds have a cytotoxic activity and can be used for the treatment of cancer.
25 junio 2007
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Junio 2007 .
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Miguel Del Corral JM, Castro MA, Lucena Rodrı Guez M, Chamorro P, Cuevas C, San Feliciano A
Departamento de Quı´mica Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, E-37007 Salamanca, Spain.
Diterpenylquinone/hydroquinone derivatives were prepared through Diels-Alder cycloaddition between natural myrcecommunic acid or its methyl ester and p-benzoquinone (p-BQ), using BF(3).Et(2)O as catalyst or under microwave (Mw) irradiation. Acetyl, methyl and benzyl derivatives of several diterpenylnaphthohydroquinone were prepared from cycloadducts following two basic synthetic strategies, either protection before aromatisation or viceversa. Some of them were further functionalised at the B-ring of the decaline core. Most of the new compounds were evaluated and some of them resulted cytotoxic against several tumour cell lines with IC(50) values under the muM level.
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Miguel Del Corral JM, Castro MA, Lucena Rodrı Guez M, Chamorro P, Cuevas C, San Feliciano A
Departamento de Quı´mica Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, E-37007 Salamanca, Spain.
Diterpenylquinone/hydroquinone derivatives were prepared through Diels-Alder cycloaddition between natural myrcecommunic acid or its methyl ester and p-benzoquinone (p-BQ), using BF(3).Et(2)O as catalyst or under microwave (Mw) irradiation. Acetyl, methyl and benzyl derivatives of several diterpenylnaphthohydroquinone were prepared from cycloadducts following two basic synthetic strategies, either protection before aromatisation or viceversa. Some of them were further functionalised at the B-ring of the decaline core. Most of the new compounds were evaluated and some of them resulted cytotoxic against several tumour cell lines with IC(50) values under the muM level.
22 junio 2007
21 junio 2007
NeuroPharma Patente : Dibenzene derivatives as calcium channel blockers .
Dibenzene derivatives as calcium channel blockers
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
19 junio 2007
18 junio 2007
Joan Vericat , de NeuroPharma , en Euronanoforum ( Alemania ) 19 al 21 Junio . Nanotechnology in Life .
Poster :
P-C10
SAFETY ASSESSMENT OF NANOMEDICINES/NANODEVICES: CURRENT GUIDELINES ARE SUFFICIENT TO ENSURE SAFETYJoan-Albert Vericat, Isolde Anglade, Nicolas Fabre Neuropharma SA, Madrid (Spain)
P-C10
SAFETY ASSESSMENT OF NANOMEDICINES/NANODEVICES: CURRENT GUIDELINES ARE SUFFICIENT TO ENSURE SAFETYJoan-Albert Vericat, Isolde Anglade, Nicolas Fabre Neuropharma SA, Madrid (Spain)
17 junio 2007
15 junio 2007
Patente EEUU , Yondelis consigue Reforzar los efectos citotóxicos del Platinum .
Combined use of Yondelis and platinum antineoplastic compounds .
Publication number: US2007128201
Publication date: 2007-06-07
Inventor: D INCALCI MAURIZIO (IT); GIANNI LUCA (IT); GIAVAZZI RAFFAELLA (IT); MARTIN MARGARITA G (ES); JUDSON IAN (GB); DONAQUE JOSE M J (ES); SESSA CRISTIANA (CH)
Applicant: PHARMA MAR S A U (ES)
Classification: - international: A61K39/395; A61K31/282; A61K31/495; A61K31/555; A61K33/24; A61P35/00; A61K39/395; A61K31/28; A61K31/495; A61K31/555; A61K33/24; A61P35/00; - European: A61K31/282; A61K31/495; A61K31/555; A61K33/24
Application number: US20040558133 20040601
Priority number(s): GB20030012407 20030529; WO2004GB02319 20040601
Abstract of US2007128201 Yondelis can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.
Publication number: US2007128201
Publication date: 2007-06-07
Inventor: D INCALCI MAURIZIO (IT); GIANNI LUCA (IT); GIAVAZZI RAFFAELLA (IT); MARTIN MARGARITA G (ES); JUDSON IAN (GB); DONAQUE JOSE M J (ES); SESSA CRISTIANA (CH)
Applicant: PHARMA MAR S A U (ES)
Classification: - international: A61K39/395; A61K31/282; A61K31/495; A61K31/555; A61K33/24; A61P35/00; A61K39/395; A61K31/28; A61K31/495; A61K31/555; A61K33/24; A61P35/00; - European: A61K31/282; A61K31/495; A61K31/555; A61K33/24
Application number: US20040558133 20040601
Priority number(s): GB20030012407 20030529; WO2004GB02319 20040601
Abstract of US2007128201 Yondelis can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.
14 junio 2007
11 junio 2007
09 junio 2007
Cronista de un Cáncer . ( El Mundo ) .
Cronista de un cáncer
En noviembre de 2006, a Deborah Charles le diagnosticaron un cáncer de mama. Desde entonces, esta periodista de 41 años se ha sometido a tres operaciones y cuatro ciclos de quimioterapia. Un compañero de su agencia la ha acompañado durante una semana. (Fotos: Jim Bourg REUTERS) .
En noviembre de 2006, a Deborah Charles le diagnosticaron un cáncer de mama. Desde entonces, esta periodista de 41 años se ha sometido a tres operaciones y cuatro ciclos de quimioterapia. Un compañero de su agencia la ha acompañado durante una semana. (Fotos: Jim Bourg REUTERS) .
08 junio 2007
Yondelis ( ET-743 ) , evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.
Huygh G, Clement PM, Dumez H, Schöffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, Van Oosterom AT.
2006 Dec 31.
Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900-1500 mug/m(2) every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16 patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical benefit rate at 3 and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neutropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This retrospective analysis confirms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion of patients.
2006 Dec 31.
Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900-1500 mug/m(2) every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16 patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical benefit rate at 3 and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neutropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This retrospective analysis confirms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion of patients.
06 junio 2007
04 junio 2007
03 junio 2007
Sylentis ( Zeltia Group ) .
Imagine the next time you join a discussion about Sylentis. When you start sharing the fascinating Sylentis facts, your friends will be absolutely amazed. The information about Sylentis presented here will do one of two things: either it will reinforce what you know about Sylentis or it will teach you something new. Both are good outcomes. It never hurts to be well-informed with the latest on Sylentis. Compare what you've learned here to future articles so that you can stay alert to changes in the area of Sylentis.
02 junio 2007
Crambescidin 800 . Accelerating the discovery of biologically active small molecules using a high-throughput yeast halo assay.
Gassner NC, Tamble CM, Bock JE, Cotton N, White KN, Tenney K, St Onge RP, Proctor MJ, Giaever G, Nislow C, Davis RW, Crews P, Holman TR, Lokey RS.
J Nat Prod. 2007 Mar;70(3):383-90. Epub 2007 Feb 10.
Department of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064, USA.
The budding yeast Saccharomyces cerevisiae, a powerful model system for the study of basic eukaryotic cell biology, has been used increasingly as a screening tool for the identification of bioactive small molecules. We have developed a novel yeast toxicity screen that is easily automated and compatible with high-throughput screening robotics. The new screen is quantitative and allows inhibitory potencies to be determined, since the diffusion of the sample provides a concentration gradient and a corresponding toxicity halo. The efficacy of this new screen was illustrated by testing materials including 3104 compounds from the NCI libraries, 167 marine sponge crude extracts, and 149 crude marine-derived fungal extracts. There were 46 active compounds among the NCI set. One very active extract was selected for bioactivity-guided fractionation, resulting in the identification of crambescidin 800 as a potent antifungal agent.
J Nat Prod. 2007 Mar;70(3):383-90. Epub 2007 Feb 10.
Department of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064, USA.
The budding yeast Saccharomyces cerevisiae, a powerful model system for the study of basic eukaryotic cell biology, has been used increasingly as a screening tool for the identification of bioactive small molecules. We have developed a novel yeast toxicity screen that is easily automated and compatible with high-throughput screening robotics. The new screen is quantitative and allows inhibitory potencies to be determined, since the diffusion of the sample provides a concentration gradient and a corresponding toxicity halo. The efficacy of this new screen was illustrated by testing materials including 3104 compounds from the NCI libraries, 167 marine sponge crude extracts, and 149 crude marine-derived fungal extracts. There were 46 active compounds among the NCI set. One very active extract was selected for bioactivity-guided fractionation, resulting in the identification of crambescidin 800 as a potent antifungal agent.
Synthesis of Pyrrolo-isoquinolines Related to the Lamellarins Using Silver-Catalyzed Cycloisomerization/Dipolar Cycloaddition.
Su S, Porco JA Jr.
J Am Chem Soc. 2007 Jun 1 .
Department of Chemistry and Center for Chemical Methodology and Library Development (CMLD-BU), Boston University, Boston, Massachusetts 02215.
Synthesis of pyrrolo-isoquinolines related to the lamellarin alkaloids employing silver-catalyzed cycloisomerization-dipolar cycloaddition of alkynyl N-benzylidene glycinates is described. Mechanistic studies revealed Ag(I)-catalyzed cycloisomerization to an azomethine ylide as a key step for formation of angular pyrrolo-isoquinolines.Date of Electronic Publication: 2007 Jun 1
J Am Chem Soc. 2007 Jun 1 .
Department of Chemistry and Center for Chemical Methodology and Library Development (CMLD-BU), Boston University, Boston, Massachusetts 02215.
Synthesis of pyrrolo-isoquinolines related to the lamellarin alkaloids employing silver-catalyzed cycloisomerization-dipolar cycloaddition of alkynyl N-benzylidene glycinates is described. Mechanistic studies revealed Ag(I)-catalyzed cycloisomerization to an azomethine ylide as a key step for formation of angular pyrrolo-isoquinolines.Date of Electronic Publication: 2007 Jun 1